Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

United Therapeutics Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63% decrease between quarters. United Therapeutics earned $162.70 million, and sales totaled $444.70 million in Q3.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.